nodes	percent_of_prediction	percent_of_DWPC	metapath
Tazarotene—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.289	0.51	CbGbCtD
Tazarotene—CYP2C8—Progesterone—uterine cancer	0.191	0.338	CbGbCtD
Tazarotene—CYP2C8—Etoposide—uterine cancer	0.0856	0.151	CbGbCtD
Tazarotene—RARA—myometrium—uterine cancer	0.0093	0.0652	CbGeAlD
Tazarotene—RXRB—decidua—uterine cancer	0.00826	0.0579	CbGeAlD
Tazarotene—RARG—decidua—uterine cancer	0.00733	0.0514	CbGeAlD
Tazarotene—RARB—female reproductive system—uterine cancer	0.00707	0.0496	CbGeAlD
Tazarotene—RARA—decidua—uterine cancer	0.00689	0.0484	CbGeAlD
Tazarotene—RARA—renal system—uterine cancer	0.00677	0.0475	CbGeAlD
Tazarotene—RARG—mammalian vulva—uterine cancer	0.00673	0.0472	CbGeAlD
Tazarotene—RARA—endometrium—uterine cancer	0.00654	0.0459	CbGeAlD
Tazarotene—RARB—female gonad—uterine cancer	0.00643	0.0451	CbGeAlD
Tazarotene—RARG—uterus—uterine cancer	0.00641	0.045	CbGeAlD
Tazarotene—RARB—vagina—uterine cancer	0.00639	0.0448	CbGeAlD
Tazarotene—Cheilitis—Dactinomycin—uterine cancer	0.00614	0.055	CcSEcCtD
Tazarotene—RARA—uterus—uterine cancer	0.00603	0.0423	CbGeAlD
Tazarotene—RXRB—female gonad—uterine cancer	0.00591	0.0415	CbGeAlD
Tazarotene—RXRB—vagina—uterine cancer	0.00587	0.0412	CbGeAlD
Tazarotene—RARG—female reproductive system—uterine cancer	0.00576	0.0404	CbGeAlD
Tazarotene—RARA—female reproductive system—uterine cancer	0.00542	0.038	CbGeAlD
Tazarotene—RARG—Nuclear Receptors—PGR—uterine cancer	0.00541	0.03	CbGpPWpGaD
Tazarotene—RARG—female gonad—uterine cancer	0.00525	0.0368	CbGeAlD
Tazarotene—RARG—vagina—uterine cancer	0.00521	0.0366	CbGeAlD
Tazarotene—RARA—female gonad—uterine cancer	0.00493	0.0346	CbGeAlD
Tazarotene—RARB—Nuclear Receptors—PGR—uterine cancer	0.00485	0.0269	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors—ESR2—uterine cancer	0.00476	0.0264	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—PGR—uterine cancer	0.00465	0.0258	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—PGR—uterine cancer	0.00465	0.0258	CbGpPWpGaD
Tazarotene—Acne—Progesterone—uterine cancer	0.00439	0.0393	CcSEcCtD
Tazarotene—RARG—Nuclear Receptor transcription pathway—PGR—uterine cancer	0.00428	0.0237	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors—ESR2—uterine cancer	0.00427	0.0237	CbGpPWpGaD
Tazarotene—RARB—lymph node—uterine cancer	0.00413	0.029	CbGeAlD
Tazarotene—RXRB—Nuclear Receptors—ESR2—uterine cancer	0.0041	0.0227	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—ESR2—uterine cancer	0.0041	0.0227	CbGpPWpGaD
Tazarotene—Skin discolouration—Progesterone—uterine cancer	0.00409	0.0366	CcSEcCtD
Tazarotene—Acne—Medroxyprogesterone Acetate—uterine cancer	0.00398	0.0356	CcSEcCtD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—YWHAE—uterine cancer	0.00388	0.0215	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptor transcription pathway—PGR—uterine cancer	0.00384	0.0213	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.00376	0.0209	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—PGR—uterine cancer	0.00368	0.0204	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—PGR—uterine cancer	0.00368	0.0204	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.00353	0.0196	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.00339	0.0188	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.00338	0.0187	CbGpPWpGaD
Tazarotene—RARG—lymph node—uterine cancer	0.00337	0.0237	CbGeAlD
Tazarotene—RARA—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.00324	0.018	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.00324	0.018	CbGpPWpGaD
Tazarotene—RARA—lymph node—uterine cancer	0.00317	0.0222	CbGeAlD
Tazarotene—Swelling—Progesterone—uterine cancer	0.00304	0.0272	CcSEcCtD
Tazarotene—Sensitisation—Epirubicin—uterine cancer	0.00297	0.0265	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors—ESR1—uterine cancer	0.00289	0.016	CbGpPWpGaD
Tazarotene—Swelling—Medroxyprogesterone Acetate—uterine cancer	0.00276	0.0246	CcSEcCtD
Tazarotene—Sensitisation—Doxorubicin—uterine cancer	0.00275	0.0246	CcSEcCtD
Tazarotene—CYP2C8—renal system—uterine cancer	0.00268	0.0188	CbGeAlD
Tazarotene—CYP2C8—endometrium—uterine cancer	0.00259	0.0182	CbGeAlD
Tazarotene—RARB—Nuclear Receptors—ESR1—uterine cancer	0.00259	0.0144	CbGpPWpGaD
Tazarotene—Leukoderma—Epirubicin—uterine cancer	0.00249	0.0223	CcSEcCtD
Tazarotene—RARA—Nuclear Receptors—ESR1—uterine cancer	0.00248	0.0138	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—ESR1—uterine cancer	0.00248	0.0138	CbGpPWpGaD
Tazarotene—Leukoderma—Doxorubicin—uterine cancer	0.00231	0.0206	CcSEcCtD
Tazarotene—RARG—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.00228	0.0127	CbGpPWpGaD
Tazarotene—Dry skin—Medroxyprogesterone Acetate—uterine cancer	0.00223	0.0199	CcSEcCtD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—MET—uterine cancer	0.00218	0.0121	CbGpPWpGaD
Tazarotene—CYP2C8—female reproductive system—uterine cancer	0.00215	0.0151	CbGeAlD
Tazarotene—Pain—Carboplatin—uterine cancer	0.00215	0.0192	CcSEcCtD
Tazarotene—Skin discolouration—Etoposide—uterine cancer	0.00209	0.0187	CcSEcCtD
Tazarotene—RARG—Retinoic acid receptors-mediated signaling—EP300—uterine cancer	0.00208	0.0116	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.00205	0.0114	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.00197	0.0109	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.00196	0.0109	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.00196	0.0109	CbGpPWpGaD
Tazarotene—Inflammation—Etoposide—uterine cancer	0.00195	0.0174	CcSEcCtD
Tazarotene—CYP2C8—vagina—uterine cancer	0.00194	0.0136	CbGeAlD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.00189	0.0105	CbGpPWpGaD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—CDH1—uterine cancer	0.00189	0.0105	CbGpPWpGaD
Tazarotene—RARB—Retinoic acid receptors-mediated signaling—EP300—uterine cancer	0.00187	0.0104	CbGpPWpGaD
Tazarotene—Haemoglobin—Progesterone—uterine cancer	0.00187	0.0167	CcSEcCtD
Tazarotene—Haemorrhage—Progesterone—uterine cancer	0.00186	0.0166	CcSEcCtD
Tazarotene—Oedema peripheral—Progesterone—uterine cancer	0.00183	0.0164	CcSEcCtD
Tazarotene—Skin exfoliation—Etoposide—uterine cancer	0.0018	0.0161	CcSEcCtD
Tazarotene—RARA—Retinoic acid receptors-mediated signaling—EP300—uterine cancer	0.00179	0.00994	CbGpPWpGaD
Tazarotene—RXRB—Retinoic acid receptors-mediated signaling—EP300—uterine cancer	0.00179	0.00994	CbGpPWpGaD
Tazarotene—Skin hyperpigmentation—Epirubicin—uterine cancer	0.00178	0.0159	CcSEcCtD
Tazarotene—RARA—Adipogenesis—HMGA1—uterine cancer	0.00174	0.00965	CbGpPWpGaD
Tazarotene—Haemoglobin—Medroxyprogesterone Acetate—uterine cancer	0.00169	0.0151	CcSEcCtD
Tazarotene—Haemorrhage—Medroxyprogesterone Acetate—uterine cancer	0.00168	0.015	CcSEcCtD
Tazarotene—Oedema peripheral—Medroxyprogesterone Acetate—uterine cancer	0.00166	0.0148	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Doxorubicin—uterine cancer	0.00165	0.0147	CcSEcCtD
Tazarotene—Erythema—Progesterone—uterine cancer	0.00162	0.0145	CcSEcCtD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—ERBB2—uterine cancer	0.00159	0.00883	CbGpPWpGaD
Tazarotene—Swelling—Etoposide—uterine cancer	0.00156	0.0139	CcSEcCtD
Tazarotene—Burning sensation—Epirubicin—uterine cancer	0.00153	0.0136	CcSEcCtD
Tazarotene—Blister—Epirubicin—uterine cancer	0.00147	0.0132	CcSEcCtD
Tazarotene—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.0131	CcSEcCtD
Tazarotene—Burning sensation—Doxorubicin—uterine cancer	0.00141	0.0126	CcSEcCtD
Tazarotene—Blister—Doxorubicin—uterine cancer	0.00136	0.0122	CcSEcCtD
Tazarotene—Discomfort—Progesterone—uterine cancer	0.00136	0.0122	CcSEcCtD
Tazarotene—Oedema—Progesterone—uterine cancer	0.00132	0.0118	CcSEcCtD
Tazarotene—Stinging—Epirubicin—uterine cancer	0.00131	0.0117	CcSEcCtD
Tazarotene—RARA—Adipogenesis—SOCS3—uterine cancer	0.0013	0.00722	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.00127	0.00702	CbGpPWpGaD
Tazarotene—RARG—Retinoic acid receptors-mediated signaling—AKT1—uterine cancer	0.00126	0.00698	CbGpPWpGaD
Tazarotene—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00123	0.011	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.00121	0.00673	CbGpPWpGaD
Tazarotene—Stinging—Doxorubicin—uterine cancer	0.00121	0.0108	CcSEcCtD
Tazarotene—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.00119	0.0107	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.00117	0.00651	CbGpPWpGaD
Tazarotene—Skin discolouration—Epirubicin—uterine cancer	0.00117	0.0105	CcSEcCtD
Tazarotene—Erythema—Dactinomycin—uterine cancer	0.00114	0.0102	CcSEcCtD
Tazarotene—RARA—Adipogenesis—SMAD3—uterine cancer	0.00114	0.00631	CbGpPWpGaD
Tazarotene—RXRB—Regulation of Androgen receptor activity—EP300—uterine cancer	0.00114	0.0063	CbGpPWpGaD
Tazarotene—RARB—Retinoic acid receptors-mediated signaling—AKT1—uterine cancer	0.00113	0.00626	CbGpPWpGaD
Tazarotene—Pain—Progesterone—uterine cancer	0.00113	0.0101	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.00113	0.00624	CbGpPWpGaD
Tazarotene—Inflammation—Epirubicin—uterine cancer	0.00109	0.00977	CcSEcCtD
Tazarotene—Skin discolouration—Doxorubicin—uterine cancer	0.00109	0.00971	CcSEcCtD
Tazarotene—RARA—Retinoic acid receptors-mediated signaling—AKT1—uterine cancer	0.00108	0.006	CbGpPWpGaD
Tazarotene—RXRB—Retinoic acid receptors-mediated signaling—AKT1—uterine cancer	0.00108	0.006	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.00107	0.00591	CbGpPWpGaD
Tazarotene—Dermatitis contact—Epirubicin—uterine cancer	0.00105	0.00937	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.00102	0.00567	CbGpPWpGaD
Tazarotene—Skin exfoliation—Epirubicin—uterine cancer	0.00101	0.00905	CcSEcCtD
Tazarotene—Inflammation—Doxorubicin—uterine cancer	0.00101	0.00904	CcSEcCtD
Tazarotene—RARG—Gene Expression—PHF1—uterine cancer	0.001	0.00556	CbGpPWpGaD
Tazarotene—Dermatitis contact—Doxorubicin—uterine cancer	0.000969	0.00867	CcSEcCtD
Tazarotene—Discomfort—Dactinomycin—uterine cancer	0.00096	0.00859	CcSEcCtD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—PIK3CA—uterine cancer	0.000958	0.00531	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000956	0.0053	CbGpPWpGaD
Tazarotene—Skin exfoliation—Doxorubicin—uterine cancer	0.000936	0.00837	CcSEcCtD
Tazarotene—Pruritus—Progesterone—uterine cancer	0.000933	0.00834	CcSEcCtD
Tazarotene—Oedema—Dactinomycin—uterine cancer	0.000932	0.00834	CcSEcCtD
Tazarotene—CYP2C8—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000916	0.00508	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000916	0.00508	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PHF1—uterine cancer	0.000899	0.00498	CbGpPWpGaD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—HRAS—uterine cancer	0.000886	0.00492	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PHF1—uterine cancer	0.000862	0.00478	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PHF1—uterine cancer	0.000862	0.00478	CbGpPWpGaD
Tazarotene—Eczema—Epirubicin—uterine cancer	0.000856	0.00766	CcSEcCtD
Tazarotene—RARG—Gene Expression—CHD4—uterine cancer	0.000852	0.00473	CbGpPWpGaD
Tazarotene—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000845	0.00756	CcSEcCtD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000839	0.00465	CbGpPWpGaD
Tazarotene—Rash—Progesterone—uterine cancer	0.000831	0.00744	CcSEcCtD
Tazarotene—Dermatitis—Progesterone—uterine cancer	0.000831	0.00743	CcSEcCtD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000828	0.00459	CbGpPWpGaD
Tazarotene—Dermatitis bullous—Epirubicin—uterine cancer	0.000805	0.0072	CcSEcCtD
Tazarotene—Pain—Dactinomycin—uterine cancer	0.000797	0.00713	CcSEcCtD
Tazarotene—Eczema—Doxorubicin—uterine cancer	0.000792	0.00708	CcSEcCtD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—AKT1—uterine cancer	0.000783	0.00434	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—CHD4—uterine cancer	0.000764	0.00424	CbGpPWpGaD
Tazarotene—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000753	0.00674	CcSEcCtD
Tazarotene—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000753	0.00673	CcSEcCtD
Tazarotene—Dermatitis bullous—Doxorubicin—uterine cancer	0.000745	0.00666	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—PGR—uterine cancer	0.000739	0.0041	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—CHD4—uterine cancer	0.000733	0.00406	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—CHD4—uterine cancer	0.000733	0.00406	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—SUZ12—uterine cancer	0.000714	0.00396	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000712	0.00395	CbGpPWpGaD
Tazarotene—Dry skin—Epirubicin—uterine cancer	0.000705	0.00631	CcSEcCtD
Tazarotene—Discomfort—Etoposide—uterine cancer	0.000695	0.00622	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000683	0.00379	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.00068	0.00377	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—PGR—uterine cancer	0.000662	0.00367	CbGpPWpGaD
Tazarotene—Dry skin—Doxorubicin—uterine cancer	0.000652	0.00584	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—ESR2—uterine cancer	0.00065	0.00361	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—SUZ12—uterine cancer	0.00064	0.00355	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—AKR1B10—uterine cancer	0.00064	0.00355	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—PGR—uterine cancer	0.000635	0.00352	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—PGR—uterine cancer	0.000635	0.00352	CbGpPWpGaD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000617	0.00342	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—SUZ12—uterine cancer	0.000614	0.00341	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—SUZ12—uterine cancer	0.000614	0.00341	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000609	0.00338	CbGpPWpGaD
Tazarotene—Photosensitivity reaction—Epirubicin—uterine cancer	0.000607	0.00543	CcSEcCtD
Tazarotene—RARA—Adipogenesis—CTNNB1—uterine cancer	0.000596	0.00331	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—AKR1B1—uterine cancer	0.000595	0.0033	CbGpPWpGaD
Tazarotene—Rash—Dactinomycin—uterine cancer	0.000588	0.00526	CcSEcCtD
Tazarotene—RARB—Generic Transcription Pathway—ESR2—uterine cancer	0.000583	0.00323	CbGpPWpGaD
Tazarotene—Pain—Etoposide—uterine cancer	0.000577	0.00516	CcSEcCtD
Tazarotene—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000562	0.00502	CcSEcCtD
Tazarotene—RXRB—Generic Transcription Pathway—ESR2—uterine cancer	0.000559	0.0031	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—ESR2—uterine cancer	0.000559	0.0031	CbGpPWpGaD
Tazarotene—Haemoglobin—Epirubicin—uterine cancer	0.000535	0.00478	CcSEcCtD
Tazarotene—Haemorrhage—Epirubicin—uterine cancer	0.000532	0.00476	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000529	0.00294	CbGpPWpGaD
Tazarotene—Oedema peripheral—Epirubicin—uterine cancer	0.000524	0.00469	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000523	0.0029	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000501	0.00278	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.0005	0.00277	CbGpPWpGaD
Tazarotene—Haemoglobin—Doxorubicin—uterine cancer	0.000495	0.00443	CcSEcCtD
Tazarotene—Haemorrhage—Doxorubicin—uterine cancer	0.000492	0.0044	CcSEcCtD
Tazarotene—Oedema peripheral—Doxorubicin—uterine cancer	0.000485	0.00434	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000484	0.00268	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—SMAD3—uterine cancer	0.000483	0.00268	CbGpPWpGaD
Tazarotene—Pruritus—Etoposide—uterine cancer	0.000477	0.00427	CcSEcCtD
Tazarotene—RARB—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000475	0.00263	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000464	0.00257	CbGpPWpGaD
Tazarotene—Erythema—Epirubicin—uterine cancer	0.000463	0.00414	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000457	0.00254	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000455	0.00252	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000455	0.00252	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000446	0.00247	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000438	0.00243	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—AKR1C1—uterine cancer	0.000437	0.00242	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—SMAD3—uterine cancer	0.000433	0.0024	CbGpPWpGaD
Tazarotene—Erythema—Doxorubicin—uterine cancer	0.000429	0.00383	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000427	0.00237	CbGpPWpGaD
Tazarotene—Rash—Etoposide—uterine cancer	0.000425	0.0038	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.000425	0.00236	CbGpPWpGaD
Tazarotene—Dermatitis—Etoposide—uterine cancer	0.000425	0.0038	CcSEcCtD
Tazarotene—RARA—Generic Transcription Pathway—SMAD3—uterine cancer	0.000416	0.0023	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—SMAD3—uterine cancer	0.000416	0.0023	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.000407	0.00226	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	0.000403	0.00223	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—ESR1—uterine cancer	0.000394	0.00219	CbGpPWpGaD
Tazarotene—Discomfort—Epirubicin—uterine cancer	0.00039	0.00349	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	0.000386	0.00214	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—GPX3—uterine cancer	0.000384	0.00213	CbGpPWpGaD
Tazarotene—Oedema—Epirubicin—uterine cancer	0.000378	0.00338	CcSEcCtD
Tazarotene—CYP2C8—Biological oxidations—CYP11A1—uterine cancer	0.000361	0.002	CbGpPWpGaD
Tazarotene—Discomfort—Doxorubicin—uterine cancer	0.000361	0.00323	CcSEcCtD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP11A1—uterine cancer	0.000356	0.00198	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—PGR—uterine cancer	0.000356	0.00197	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—ESR1—uterine cancer	0.000354	0.00196	CbGpPWpGaD
Tazarotene—Oedema—Doxorubicin—uterine cancer	0.00035	0.00313	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	0.000342	0.0019	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—ESR1—uterine cancer	0.000339	0.00188	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—ESR1—uterine cancer	0.000339	0.00188	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—EZH2—uterine cancer	0.000338	0.00187	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—AKR1C3—uterine cancer	0.000336	0.00187	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	0.000328	0.00182	CbGpPWpGaD
Tazarotene—Pain—Epirubicin—uterine cancer	0.000323	0.00289	CcSEcCtD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000321	0.00178	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PGR—uterine cancer	0.000319	0.00177	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	0.000314	0.00174	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ESR2—uterine cancer	0.000313	0.00174	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PGR—uterine cancer	0.000306	0.0017	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PGR—uterine cancer	0.000306	0.0017	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	0.000304	0.00169	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—EZH2—uterine cancer	0.000303	0.00168	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	0.000301	0.00167	CbGpPWpGaD
Tazarotene—Pain—Doxorubicin—uterine cancer	0.000299	0.00268	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	0.000292	0.00162	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—EZH2—uterine cancer	0.00029	0.00161	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—EZH2—uterine cancer	0.00029	0.00161	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—ESR2—uterine cancer	0.000281	0.00156	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—ESR2—uterine cancer	0.000269	0.00149	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ESR2—uterine cancer	0.000269	0.00149	CbGpPWpGaD
Tazarotene—Pruritus—Epirubicin—uterine cancer	0.000267	0.00239	CcSEcCtD
Tazarotene—CYP2C8—Biological oxidations—CYP19A1—uterine cancer	0.000266	0.00147	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP19A1—uterine cancer	0.000262	0.00145	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	0.000257	0.00142	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—CDKN2B—uterine cancer	0.000255	0.00141	CbGpPWpGaD
Tazarotene—Pruritus—Doxorubicin—uterine cancer	0.000247	0.00221	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	0.000246	0.00137	CbGpPWpGaD
Tazarotene—Rash—Epirubicin—uterine cancer	0.000238	0.00213	CcSEcCtD
Tazarotene—Dermatitis—Epirubicin—uterine cancer	0.000238	0.00213	CcSEcCtD
Tazarotene—RARG—Gene Expression—SMAD3—uterine cancer	0.000233	0.00129	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000232	0.00129	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000232	0.00129	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—CDKN2B—uterine cancer	0.000229	0.00127	CbGpPWpGaD
Tazarotene—Rash—Doxorubicin—uterine cancer	0.000221	0.00197	CcSEcCtD
Tazarotene—Dermatitis—Doxorubicin—uterine cancer	0.00022	0.00197	CcSEcCtD
Tazarotene—RXRB—Gene Expression—CDKN2B—uterine cancer	0.000219	0.00122	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—CDKN2B—uterine cancer	0.000219	0.00122	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—SMAD3—uterine cancer	0.000209	0.00116	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—SMAD3—uterine cancer	0.0002	0.00111	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—SMAD3—uterine cancer	0.0002	0.00111	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ESR1—uterine cancer	0.00019	0.00105	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—ESR1—uterine cancer	0.00017	0.000944	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.00017	0.000943	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ESR1—uterine cancer	0.000163	0.000905	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—ESR1—uterine cancer	0.000163	0.000905	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SRD5A2—uterine cancer	0.000143	0.000792	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NDUFB11—uterine cancer	0.000143	0.000792	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000139	0.000769	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000131	0.000726	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—AKR1B1—uterine cancer	0.000103	0.000572	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—STAR—uterine cancer	0.000103	0.000572	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000102	0.000566	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—POLD1—uterine cancer	8.1e-05	0.000449	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—AKR1C1—uterine cancer	7.58e-05	0.00042	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—AKT1—uterine cancer	6.85e-05	0.00038	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—RRM2—uterine cancer	6.75e-05	0.000374	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—DCN—uterine cancer	6.56e-05	0.000364	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP11A1—uterine cancer	6.18e-05	0.000343	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—AKT1—uterine cancer	6.14e-05	0.000341	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—AKT1—uterine cancer	5.89e-05	0.000327	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—AKT1—uterine cancer	5.89e-05	0.000327	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—AKR1C3—uterine cancer	5.83e-05	0.000323	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—STK11—uterine cancer	4.54e-05	0.000252	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP19A1—uterine cancer	4.54e-05	0.000252	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.27e-05	0.000237	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.07e-05	0.000226	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—MTHFR—uterine cancer	3.41e-05	0.000189	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.01e-05	0.000167	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PTEN—uterine cancer	1.9e-05	0.000105	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—EP300—uterine cancer	1.81e-05	0.0001	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PIK3CA—uterine cancer	1.34e-05	7.43e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—AKT1—uterine cancer	1.09e-05	6.07e-05	CbGpPWpGaD
